Short- and Long-Term Effect of Parkinson’s Disease Multimodal Complex Treatment

Parkinson´s disease multimodal complex treatment (PD-MCT) is a multidisciplinary inpatient treatment option increasingly applied in Germany. However, data on its effectiveness are rare. Data were collected at the Department of Neurology of the University Hospital Jena, Germany. In 2019, 159 patients...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Konstantin G. Heimrich, Tino Prell
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	Parkinson’s disease multidisciplinary care health services research depression quality of life Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/28f6e899dc6042afb98a5bd77f7ddaec
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:28f6e899dc6042afb98a5bd77f7ddaec
record_format	dspace
spelling	oai:doaj.org-article:28f6e899dc6042afb98a5bd77f7ddaec2021-11-25T16:57:50ZShort- and Long-Term Effect of Parkinson’s Disease Multimodal Complex Treatment10.3390/brainsci111114602076-3425https://doaj.org/article/28f6e899dc6042afb98a5bd77f7ddaec2021-11-01T00:00:00Zhttps://www.mdpi.com/2076-3425/11/11/1460https://doaj.org/toc/2076-3425Parkinson´s disease multimodal complex treatment (PD-MCT) is a multidisciplinary inpatient treatment option increasingly applied in Germany. However, data on its effectiveness are rare. Data were collected at the Department of Neurology of the University Hospital Jena, Germany. In 2019, 159 patients were admitted to our neurology ward for PD-MCT. Patients were followed for up to 12 months, and their data were retrospectively analyzed to assess the short- and long-term treatment effects. The treatment led to an improvement in motor function assessed by Movement Disorder Society sponsored revision of the unified Parkinson´s disease rating scale part III (MDS-UPDRS III) and motor performance (Tinetti test). Improvement of MDS-UPDRS III was associated with lower age, higher MDS-UPDRS III at admission, and less depression (assessed by Hospital Anxiety and Depression Scale and Beck-Depression Inventory II). One month after the hospital stay, 36.8% of the patients reported feeling better, while 32.6% reported feeling worse. If the patients were not depressed, they were more likely to have reported feeling better. PD-MCT is an effective inpatient treatment option. However, to improve patients’ satisfaction, screening and treatment for depression is essential. The effectiveness of different treatment durations has to be elucidated in further studies.Konstantin G. HeimrichTino PrellMDPI AGarticleParkinson’s diseasemultidisciplinary carehealth services researchdepressionquality of lifeNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENBrain Sciences, Vol 11, Iss 1460, p 1460 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Parkinson’s disease multidisciplinary care health services research depression quality of life Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	Parkinson’s disease multidisciplinary care health services research depression quality of life Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Konstantin G. Heimrich Tino Prell Short- and Long-Term Effect of Parkinson’s Disease Multimodal Complex Treatment
description	Parkinson´s disease multimodal complex treatment (PD-MCT) is a multidisciplinary inpatient treatment option increasingly applied in Germany. However, data on its effectiveness are rare. Data were collected at the Department of Neurology of the University Hospital Jena, Germany. In 2019, 159 patients were admitted to our neurology ward for PD-MCT. Patients were followed for up to 12 months, and their data were retrospectively analyzed to assess the short- and long-term treatment effects. The treatment led to an improvement in motor function assessed by Movement Disorder Society sponsored revision of the unified Parkinson´s disease rating scale part III (MDS-UPDRS III) and motor performance (Tinetti test). Improvement of MDS-UPDRS III was associated with lower age, higher MDS-UPDRS III at admission, and less depression (assessed by Hospital Anxiety and Depression Scale and Beck-Depression Inventory II). One month after the hospital stay, 36.8% of the patients reported feeling better, while 32.6% reported feeling worse. If the patients were not depressed, they were more likely to have reported feeling better. PD-MCT is an effective inpatient treatment option. However, to improve patients’ satisfaction, screening and treatment for depression is essential. The effectiveness of different treatment durations has to be elucidated in further studies.
format	article
author	Konstantin G. Heimrich Tino Prell
author_facet	Konstantin G. Heimrich Tino Prell
author_sort	Konstantin G. Heimrich
title	Short- and Long-Term Effect of Parkinson’s Disease Multimodal Complex Treatment
title_short	Short- and Long-Term Effect of Parkinson’s Disease Multimodal Complex Treatment
title_full	Short- and Long-Term Effect of Parkinson’s Disease Multimodal Complex Treatment
title_fullStr	Short- and Long-Term Effect of Parkinson’s Disease Multimodal Complex Treatment
title_full_unstemmed	Short- and Long-Term Effect of Parkinson’s Disease Multimodal Complex Treatment
title_sort	short- and long-term effect of parkinson’s disease multimodal complex treatment
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/28f6e899dc6042afb98a5bd77f7ddaec
work_keys_str_mv	AT konstantingheimrich shortandlongtermeffectofparkinsonsdiseasemultimodalcomplextreatment AT tinoprell shortandlongtermeffectofparkinsonsdiseasemultimodalcomplextreatment
_version_	1718412826974879744

Short- and Long-Term Effect of Parkinson’s Disease Multimodal Complex Treatment

Ejemplares similares